Drug Profile
Research programme: hepatitis C virus NS5B polymerase inhibitors - Boehringer Ingelheim
Latest Information Update: 24 Sep 2012
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim (Canada); Boehringer Ingelheim Pharma KG
- Developer Boehringer Ingelheim (Canada)
- Class Benzimidazoles
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 18 Sep 2012 Discontinued - Preclinical for Hepatitis C in Canada (unspecified route)
- 06 May 2003 Preclinical trials in Hepatitis C treatment in Canada (unspecified route)
- 06 May 2003 Preclinical trials in Hepatitis C treatment in Germany (unspecified route)